GlassScriptPhysician profile
Gital Patel
NPI 1174714984
$7,577.75
in general payments reported to CMS, 2019-2025
26 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $559 · 2021: $1,133 · 2022: $1,208 · 2023: $882 · 2024: $1,327 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Education: $142 · Consulting Fee: $68.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.21 |
| Education | $141.81 |
| Consulting Fee | $68.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,166.60 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,021.65 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $816.48 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $765.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $727.91 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $530.97 | 2019-2025 | |
| Pfizer INC. | $400.33 | 2019-2025 | |
| Octapharma USA, INC. | $363.20 | 2021-2025 | Cutaquig, Panzyga |
| Optinose US, INC. | $288.17 | 2019-2025 | |
| Amgen INC. | $217.61 | 2022-2025 | Repatha, Tezspire |
| Kaleo, INC. | $178.32 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $166.33 | 2022-2025 | Xembify, Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $151.95 | 2021-2023 | |
| Pharming Healthcare, INC. | $112.73 | 2019-2024 | Ruconest |
| Genentech USA, INC. | $95.76 | 2019-2024 | Xolair |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $85.94 | 2025 | Sajazir |
| Ars Pharmaceuticals Operations, INC. | $83.92 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $75.41 | 2022-2024 | Cuvitru |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Adma Biomanufacturing LLC | $68.71 | 2023-2025 | |
| Blueprint Medicines Corporation | $46.94 | 2022-2023 | Ayvakit |
| Hikma Pharmaceuticals USA | $45.30 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $44.29 | 2022 | |
| Ionis Pharmaceuticals, INC. | $24.10 | 2025 | Dawnzera |
| Uswm, LLC | $15.19 | 2021 | |
| Bio Products Laboratory USA, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gital Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.